Peptide education
N-Acetyl Semax Amidate
NA Semax Amidate
N-Acetyl Semax Amidate is Semax with both ends chemically capped: an acetyl group on the N-terminus and an amide on the C-terminus, sold online as Ac-Semax-NH2. The molecule is real and cataloged, with its own PubChem record, CAS number, and formula. What it does not have is a single published human study: exact-phrase searches of PubMed and ClinicalTrials.gov return nothing. Every benefit claim attached to it, focus, memory, BDNF, neuroprotection, stronger Semax, is borrowed from parent Semax, which is a different molecule.
A real molecule with a registry entry and an active market, and zero published human studies behind it. The entire case for it is borrowed from parent Semax, and even that source literature is limited.
Overview
Quick answer
Most human Semax evidence is for parent Semax, not N-Acetyl Semax Amidate. The online market often borrows focus, memory, BDNF, stroke, and neuroprotection claims from parent Semax. Direct human efficacy, pharmacokinetic, and safety evidence for the exact amidated analogue is still missing.
What is it?
A terminally modified Semax analog: the Semax sequence with an acetyl cap on one end and an amide cap on the other. Chemical databases treat it as its own compound, distinct from parent Semax, which means parent Semax studies do not automatically describe it.
What do people use it for or talk about?
Focus, memory, motivation, mood, BDNF, neuroprotection, and the recurring pitch that it is Semax but stronger or longer-lasting. All of that comes from vendors, forums, and parent-Semax biology. None of it comes from a trial of this molecule.
What routes and amounts show up?
Nasal sprays and research-use powders, with community reports around 100 to 300 mcg per day, once daily or split, in 2 to 4 week runs. The stated logic is that the modified version lasts longer, so less is needed. That logic has never been tested in humans, so these numbers are market convention, not a studied regimen.
Which evidence applies to the exact analogue?
Almost none of what gets cited. The stroke, rehabilitation, and optic nerve papers studied parent Semax. The BDNF findings are parent Semax in rats or stroke patients. For Ac-Semax-NH2 itself, the published record is empty.
Reported practice
Commonly reported protocol
Community modified-analog ranges. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Chemical and analytical-market listings describe N-Acetyl Semax Amidate as a distinct terminally modified Semax-family analogue, with formula C39H54N10O10S and molecular weight about 855 g/mol. That supports identity separation from parent Semax, not any clinical effect.
No peer-reviewed human efficacy or safety trial is established for the exact Ac-Semax-NH2 amidated analogue.
Parent Semax has small human studies and stroke-related literature, but those studies cover a different molecule and cannot be used as direct evidence for N-Acetyl Semax Amidate.
FDA materials discuss Semax in compounding-risk and enforcement contexts, including aggregation, peptide-related impurities, and limited safety information for proposed routes.
FDA peptide-compounding materials make identity, impurities, route, and finished-product controls central. Vendor listings or COAs are product-specific claims, not category-wide safety or efficacy evidence.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| N-Acetyl Semax Amidate improves focus, memory, or motivation. | Exact-variant human cognition trials were not found. The Semax-family human citations are parent-Semax literature, mainly stroke, rehabilitation, and optic-nerve contexts. | Parent Semax has preclinical neurotrophin, monoamine, transcriptomic, and enzyme-related literature. That biology explains why people discuss cognition; exact-variant duration, potency, route safety, and outcomes still need their own data. | Vendor listings and online discussion often present the analogue as a nootropic or focus peptide, with nasal spray and research-use formats appearing in the market. | People do talk about it as a Semax-family nootropic. The exact analogue still lacks human outcome data in the cited sources. |
| It raises BDNF in people. | The BDNF human evidence used here comes from a parent-Semax ischemic stroke paper, not from N-Acetyl Semax Amidate. That study involved stroke patients, not healthy-person BDNF or cognitive-enhancement claims. | Parent-Semax animal studies report neurotrophin-related effects, including BDNF and TrkB expression in brain regions. Those are parent-compound and animal findings. | BDNF language is common in online nootropic marketing because it sounds mechanistic and appealing, but the exact analogue lacks direct human biomarker evidence. | Parent-Semax BDNF findings can explain why the analog is marketed this way, but they do not show BDNF changes or cognitive benefit for Ac-Semax-NH2. |
| It is just Semax but stronger, longer acting, or more bioavailable. | No direct human pharmacokinetic, duration, or head-to-head evidence for N-Acetyl Semax Amidate is established for the exact analogue. | Terminal acetylation and amidation can plausibly change charge state, stability, and biological activity. Parent-Semax route-comparison data also warn against assuming that every Semax-family form behaves the same way. | Market language often treats acetylated or amidated Semax variants as improved versions. That is a seller and anecdote-driven claim, not a human PK result. | This remains a hypothesis until exact-variant human exposure data exist. |
| A 99% purity COA verifies a current vial or spray. | Human studies do not confirm a current retail vial or spray. Product testing is separate from clinical efficacy. | For nasal or injectable peptide products, identity, concentration, mass accuracy, sterility, endotoxin, microbial testing, heavy metals, storage, aggregation, and degradation all matter. HPLC purity alone does not cover those questions. | Public COAs and seller pages can vary in how much identity, assay, lot, and route safety information they show. Without lot-linked testing relevant to the route, they remain product-quality claims rather than clinical evidence. | Incomplete. A purity number is useful only as one small part of product-quality evidence. |
| It is an FDA-approved or clinically accepted Semax product. | No FDA approval or U.S. trial-registration support is established for N-Acetyl Semax Amidate. FDA materials instead discuss Semax-related bulk substances and compounded Semax safety concerns. | Mechanism and identity are not the same as approval. A chemical identity entry is not a finished, approved medicine. | Gray-market sellers may use lab or research language, but that does not make the compound an FDA-approved product. | The cited sources do not identify it as an FDA-approved or clinically accepted U.S. Semax product. |
Bottom line
Main takeaway
N-Acetyl Semax Amidate is a chemically tweaked Semax sold as a stronger version. The tweak is real; the evidence for it is not: no published human study has tested this exact molecule.
Keep four things separate: parent Semax studies, acetylated-Semax chemistry, the fully amidated Ac-Semax-NH2 molecule, and whatever is actually in a given spray or vial. Vendor pages routinely blur the first three.
Verify identity before anything else, since some listings reuse parent-Semax identity details for the amidated analog. The missing pieces are direct human efficacy, route-specific pharmacokinetics, chronic safety, and lot-linked testing.
Identity
What it is
Parent Semax is the seven-amino-acid ACTH fragment Met-Glu-His-Phe-Pro-Gly-Pro. N-Acetyl Semax Amidate is that same sequence with the N-terminus acetylated and the C-terminus amidated, a standard medicinal-chemistry move meant to slow enzymatic breakdown.
The modifications are chemically plausible, and plausibility is where the evidence stops. Terminal changes can alter stability, charge, and biological activity in either direction, and no published study has characterized what they do here. The compound exists in chemical registries and vendor catalogs, not in the trial literature.
The practical problem is naming. Seller pages blur parent Semax, acetylated Semax, and the amidated analog, sometimes reusing parent-Semax identity details on analog listings. A reader who does not check which molecule a source actually studied will absorb parent-compound evidence as if it belonged to this one.
How people talk about it online
The pitch online is Semax, but better: stronger, longer-acting, more bioavailable, usually with focus, memory, motivation, and BDNF language attached. The arguments are chemistry logic and parent-Semax reputation, presented as if they were results.
The market itself is telling: spray-labeled listings that ship lyophilized powder, atomizer kits mixed with other peptides, COAs that report purity while leaving mass-spec, endotoxin, sterility, and microbial fields blank. That is what an untested compound looks like in commerce.
Community dosing, around 100 to 300 mcg daily on the theory that the analog lasts longer, is convention that hardened into protocol. Reported practice, nothing more.
Use context
Routes, doses, and cycle patterns
No tested human regimen is available for Ac-Semax-NH2. Route and amount context comes from two places: parent-Semax studies and market product listings. The first remains parent-compound evidence; the second shows how the analogue is packaged and promoted, not how it has been clinically tested.
Human studies and product labels
Exact N-Acetyl Semax Amidate human regimen
- Purpose
- Exact-variant efficacy or safety
- Context
- No human regimen in the cited exact-phrase searches
- Route
- No exact-variant human route in the cited search results
- Amount
- No exact-variant human amount in the cited search results
- Frequency
- No exact-variant human frequency in the cited search results
- Duration
- No exact-variant human duration in the cited search results
Exact-phrase PubMed and ClinicalTrials.gov searches returned no matching records when checked. That bounded result does not prove that no human documentation exists anywhere. Published parent-Semax regimen examples remain background context, not Ac-Semax-NH2 dosing evidence.
Parent Semax ischemic-stroke BDNF paper
- Purpose
- Stroke rehabilitation and BDNF context
- Context
- Parent-Semax clinical paper
- Route
- Reported as Semax study use; route details need checking in the full paper
- Amount
- 6000 mcg/day
- Frequency
- Daily during each course
- Duration
- Two 10-day courses separated by a 20-day interval
The stroke paper reported higher plasma BDNF in Semax subgroups and correlation with earlier rehabilitation timing. This is a stroke-specific parent-Semax signal, not a healthy-person or exact-variant claim.
Parent Semax optic-nerve clinical context
- Purpose
- Optic nerve disease context
- Context
- Parent-Semax clinical trial
- Route
- Intranasal drops and endonasal electrophoresis arms
- Amount
- Public citation record does not report the amount
- Frequency
- Public citation record does not report the frequency
- Duration
- Public citation record does not report the duration
This is parent Semax only. It supports specialized clinical context for the parent compound, not a general nootropic claim and not an Ac-Semax-NH2 regimen.
Real-world discussion
Community modified-analog ranges
- Purpose
- Cognition and focus discussion
- Context
- Nootropic vendors and forums
- Route
- Intranasal spray, with subcutaneous use also discussed
- Amount
- Most often around 100 to 300 mcg per day: lower than plain semax on the theory that the modified analog is longer-acting.
- Frequency
- Once daily or split into two administrations in most reports
- Duration
- Often described in 2 to 4 week runs
Like other vendor-modified analogs, this compound has no published human literature; community ranges are extrapolated from plain semax and the longer-acting claim is untested. This is reported practice, not a recommendation.
What varies
- Exact molecule: parent Semax, Ac-Semax, and Ac-Semax-NH2 can point to different chemistry, evidence, and product quality.
- Goal: focus, memory, BDNF, stroke, mood, and neuroprotection claims depend on direct evidence for the exact molecule being discussed.
- Route: nasal-spray marketing is not the same as a route-specific human PK or safety study.
- Amount: parent-Semax study doses and retail spray amounts belong in separate schedules.
- Product quality: sequence, registry identity, concentration, sterility, endotoxin, microbial testing, and storage all matter.
Human data
Human evidence
There is no direct human evidence for N-Acetyl Semax Amidate. Exact-phrase searches of PubMed and ClinicalTrials.gov returned no records for the molecule when checked. Everything cited in its favor belongs to parent Semax: the 110-patient stroke rehabilitation paper that measured plasma BDNF, the optic nerve trial, the rat neurotrophin work. Those studies describe a different molecule, and parent Semax itself has only limited human data. The analog's efficacy, pharmacokinetics, and safety are simply unstudied.
Evidence maturity
The amidated analog has a defined chemical identity and an active market, but no published human study has tested the molecule itself.
Older Russian stroke, rehabilitation, and optic nerve papers studied parent Semax, not this analog.
PubChem, CAS, and analytical listings define the exact terminally modified molecule.
Exact-phrase PubMed and ClinicalTrials.gov searches returned no matching human records.
Gray-market sprays and lyophilized vials sell "stronger Semax" claims with variable and often shallow COA documentation.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Exact N-Acetyl Semax Amidate human evidence | No human population in the cited exact-phrase search results | No matching PubMed or ClinicalTrials.gov record in the cited searches | Exact amidated analogue | The cited exact-phrase searches returned no record reporting cognitive, mood, BDNF, neuroprotection, stroke, PK, or safety outcomes for Ac-Semax-NH2. | Search results can change and cannot prove exhaustive absence. They support the narrower claim that these named public searches did not identify direct human evidence for the exact analogue. | weak |
| Parent Semax ischemic-stroke BDNF paper | 110 ischemic-stroke patients | Clinical paper with limited public design detail | Parent Semax, not N-Acetyl Semax Amidate | The paper reported higher plasma BDNF in Semax subgroups and correlation with earlier rehabilitation timing. | Stroke-specific parent-compound study; not a healthy-person nootropic study and not a direct analogue study. | weak |
| Parent Semax optic nerve disease trial | Patients with vascular, toxic-allergic, inflammatory, or partial-atrophy optic nerve disease | Parent-Semax clinical trial | Parent Semax, not N-Acetyl Semax Amidate | Reported visual-function improvements when Semax was added to the therapeutic complex. | Specialized parent-compound context; not a general vision, cognition, or exact-variant claim. | weak |
Cautions
Safety and unknowns
- The exact analogue has no established direct human safety study, route-specific PK package, chronic-use safety record, pregnancy or lactation data, drug-interaction program, or immunogenicity assessment.
- FDA materials for compounded Semax flag aggregation, peptide-related impurities, and limited safety information for proposed routes. That is directly relevant to Semax-family compounded or gray-market products.
- Parent-Semax safety notes do not settle the analogue's risk. Parent-compound literature does not provide a chronic safety package for Ac-Semax-NH2.
- Nasal products raise formulation, preservative, concentration, microbial, local-irritation, and dose-per-spray questions. Lyophilized materials add reconstitution, sterility, endotoxin, storage, and dose-math questions.
- The biggest risk is overconfidence: a lab name and a high purity number do not replace a regulated product or human data.
Product quality
A vial label is only a starting point
Some vendor pages for "N-Acetyl Semax Amidate" appear to reuse parent-Semax identity details instead of the amidated analogue's own identity details.
COA examples can vary sharply in lot specificity, assay method, identity testing, peptide content, endotoxin, sterility, and date information.
A purity percentage alone leaves practical product-quality issues: correct molecule, amount per spray, sterility, endotoxin control, microbial status, heavy metals, storage stability, and suitability for the intended route.
Identity
Parent Semax and Ac-Semax-NH2 identifiers are mixed on some public listings. Credible product-quality claims require matching formula, registry identity, sequence, and mass.
Assay depth
HPLC purity is not the same as LC-MS identity, net peptide content, endotoxin, sterility, microbial, or heavy-metals testing.
Route and formulation
A nasal spray, liquid cartridge, and lyophilized vial carry different risks for concentration, preservatives, microbial control, reconstitution, and dose-per-use math.
Lot specificity
A public COA only matters for the lot it actually identifies. Missing lot numbers, dates, certificate images, or mass values make the document weak.
Mechanism
How it is proposed to work
N-Acetyl Semax Amidate is discussed because it resembles Semax, a synthetic ACTH-fragment analogue with neurotrophin and neurotransmitter-related research. The modification at both ends of the molecule may change stability and behavior, but human translation has not been shown.
Parent Semax literature includes animal work on BDNF, TrkB, NGF, monoamine systems, transcriptomic changes after ischemia, and enkephalin-degrading enzymes. These are background mechanisms, not direct evidence for the amidated analogue.
Adjacent acetylated-Semax chemistry is a caution because terminal modification can change metal coordination and cell-model behavior. That cuts against the simple "same as Semax but better" claim.
Parent-Semax amyloid, ischemia, and neurotrophin work may explain why the compound family attracts neuroprotection claims, but exact-variant human translation remains untested.
FAQ
Common questions
Is N-acetyl semax amidate the same as semax?
No. It is a vendor-modified semax analog marketed as longer-acting, with no published literature of its own. Claims for it are extrapolated from plain semax.
How are people using it in practice?
Commonly 100 to 300 mcg per day intranasally, once daily or split into two administrations, in 2 to 4 week runs.
Is there any published evidence for it?
None for the analog. Plain semax has a Russian research literature; the amidated version is vendor-defined chemistry.
Details
Technical details
Sources
References
- 1.
PubMed. Effectiveness of Semax in acute period of hemispheric ischemic stroke 1997.
PMID:11517472 Accessed 2026-06-08.
Russian-language controlled clinical trial in acute hemispheric ischemic stroke; route and regimen context require direct-source verification before any protocol display.
- 2.
PubMed. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke 2018.
doi:10.17116/jnevro20181183261-68 PMID:29798983 Accessed 2026-06-08.
Human stroke rehabilitation study reporting BDNF, motor-performance, and Barthel-index outcomes; keep regimen details study-reported only.
- 3.
PubMed. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease 2000.
PMID:10741256 Accessed 2026-06-08.
Russian-language clinical trial comparing intranasal drops, endonasal electrophoresis, and control groups in optic nerve disease.
- 4.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 5.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 6.
PubMed. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 2007.
doi:10.1016/j.neulet.2007.02.042 PMID:17353092 Accessed 2026-06-08.
Preclinical intranasal rat study reporting neurotrophin gene-expression effects; mechanism support only.
- 7.
PubMed. Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats 2017.
doi:10.1007/s00438-017-1297-1 PMID:28255762 Accessed 2026-06-08.
Rat focal-ischemia transcriptome study; useful for mechanism context but not a human route-comparison source.
- 8.
PubMed. Nootropic and analgesic effects of Semax following different routes of administration 2010.
PMID:21268834 Accessed 2026-06-09.
Rat route-comparison study involving intranasal and intraperitoneal administration; adjacent to, but not evidence for, human subcutaneous use.
- 9.
PubChem CID 172638603. PubChem compound record for N-Acetyl Semax Amidate
Exact-compound identity, formula, CID, and molecular-weight context.
- 10.
Janoshik assay. Janoshik N-Acetyl Semax Amidate assay page
Exact-sequence and molecular-weight context for the marketed analog.
- 11.
PubMed exact-compound search. PubMed exact-phrase search for N-Acetyl Semax Amidate
Bounded exact-phrase literature search; no matching PubMed records were returned when checked on July 10, 2026.
- 12.
ClinicalTrials.gov exact-compound search. ClinicalTrials.gov exact-phrase search for N-Acetyl Semax Amidate
Bounded exact-phrase registry search; no matching studies were returned when checked on July 10, 2026.
- 13.
Limitless spray-labeled listing. Limitless Life Nootropics N-Acetyl Semax Amidate spray-labeled listing
Exact-compound spray-market and research-use labeling; the page describes the supplied form as lyophilized powder.
- 14.
Semax Polska atomizer kit listing. Semax Polska N-Acetyl Semax Amidate atomizer-kit listing
Exact-compound market example listing a 20 mg powder vial, 10 mL fluid, atomizer, and 5 mg of GHK-Cu arginate in the kit.
- 15.
Pepta Labs lyophilized vial listing. Pepta Labs N-Acetyl Semax Amidate lyophilized-vial listing
Exact-compound 10 mg lyophilized-vial and in-vitro research-use market context.
- 16.
Disclosed Labs lot NASMX26-30-001. Disclosed Labs COA mirror for lot NASMX26-30-001
Lot-specific exact-compound COA mirror showing reported purity and net peptide alongside absent mass-spec, endotoxin, sterility, heavy-metals, and microbial fields.
- 17.
Vendor COA examples. Vendor COA and analytical-page examples.
Product-specific identity, assay, purity, lot, and panel-depth limitations.
- 18.
FTC health-claims guidance. FTC Health Products Compliance Guidance.
Claim-substantiation context for nootropic and health-benefit marketing.